Status:
UNKNOWN
Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Lead Sponsor:
Umraniye Education and Research Hospital
Conditions:
Thyroid Carcinoma
Thyroid Papillary Carcinoma
Eligibility:
All Genders
17+ years
Brief Summary
In the last decades, thyroid cancer incidence has continuously increased all over the world, almost exclusively due to a sharp rise in the incidence of the papillary histologic subtype, which has the ...
Detailed Description
High-frequency ultrasound (US) is increasingly used to help distinguish malignancy in patients with solitary or multiple nodules, and US-guided fine needle aspiration (FNA) has become the gold standar...
Eligibility Criteria
Inclusion
- \>17 years all patients with benign/malign thyroid disease, total thyroidectomy is indicated/preferred by both primary surgeon and patient (signed informed consent is a must)
- All patients should have a malignancy predictive factors forms filled in
- All patients should have fine needle aspiration cytology (Bethesda category) available
- All patients should have an ultrasound evaluated according to TI-RADS
- All patients should have a final histopathology report
Exclusion
- Patients who are prepared for thyroid surgery other than total thyroidectomy procedure
- Age\<17 years
Key Trial Info
Start Date :
May 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04411290
Start Date
May 15 2020
End Date
June 1 2021
Last Update
June 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Umraniye Education and Research Hospital, Health Sciences Universit
Istanbul, Turkey (Türkiye), 34764